Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$173.1B | 5.9 | $447.8 40.4% undervalued | 19.3% | $33.4B | $10.4B | 18.6% | 31.1% | 61.5% | 11.9% | 1,022.6% | |
$743.9B | 7.0 | $225.3 72.7% overvalued | 12.9% | $45.0B | $510.8M | 32.0% | 1.1% | 81.6% | 40.7% | 235.7% | |
$398.7B | 5.9 | $197.1 18.9% undervalued | 6.2% | $88.8B | $18.1B | 4.3% | 20.3% | 69.1% | 15.7% | 51.2% | |
$375.8B | 6.0 | $302.4 41.6% undervalued | 23.2% | $56.3B | $17.8B | 3.7% | 31.7% | 73.6% | 8.3% | 1,996.0% | |
$346.3B | 7.1 | $72.1 7.7% overvalued | (40.0%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$240.8B | 7.5 | $112.5 18.8% undervalued | (20.7%) | $64.2B | $18.1B | 6.7% | 28.2% | 80.8% | 26.5% | 80.0% | |
$232.5B | 6.7 | $69.5 6.3% overvalued | 11.9% | $54.1B | $7,275.0M | 18.0% | 13.5% | 81.1% | 15.4% | 73.7% | |
$223.3B | 6.6 | $149.6 34.3% undervalued | 9.8% | $51.1B | $13.8B | 0.1% | 27.0% | 74.7% | 17.7% | 70.8% | |
$148.1B | 6.0 | $25.3 2.7% overvalued | (2.7%) | $63.6B | $9,835.0M | 8.8% | 15.5% | 65.6% | 9.0% | 71.9% | |
$146.8B | 4.7 | $91.4 55.6% undervalued | 25.2% | €44.3B | (€504.0M) | (22.5%) | (1.1%) | 70.2% | 7.4% | 23.0% | |
$143.2B | 6.1 | $91.1 20.4% overvalued | 58.1% | $28.7B | $10.5B | 6.0% | 36.4% | 78.3% | 20.1% | 138.8% |
As of today, Amgen Inc. has a stock rating of 6 (out of 10), which is considered Good.
As of today, Amgen Inc. has a Good stock rating, which is 40.4% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.